Ymdd 117

Detection of mutation using mutant-specific primers in

I, 24/28, -/+, 0.11, M, I. 11, +/-, 49.50, I, 26/27, +/-, 346.96, M, I. 12, 46/61, -/+, 47.40, -, 24/32, -/+, 0.06, V, V. 13, 72/107, -/+, 5.37, M, 66/

The Naturally Occurring Mutation among Patients Chronically

The motif has an amino acid sequence of tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) [2] and is both the binding and functional site of

Clinical features of chronic hepatitis B patients with mutation

This mutation of the tyrosine-methionine-aspartate-aspartate (YMDD) motif in the C domain of the HBV DNA polymerase gene has also been

Prevalence and Clinical Correlates of Variants during

variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. variants were examined in 794 patients in

Adefovir Dipivoxil Added to Ongoing Lamivudine in Chronic

with mutant HBV DNA. For group B, additional end points included the 8. Lai CL, Dienstag J, Schiff E, Leung N, Atkins M

Serum HBV RNA is a predictor of early emergence of the

Gastroenterology 13. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B

Background & Aims: Prolonged lamivudine therapy is associated with treatment-resistant mutant hepatitis B virus (HBV). 2003; 124: View in

[PDF] Prevalence and clinical correlates of variants during

Patients with variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require additional therapy.

Long-Term Follow-Up Study of Chinese Patients with

with mutations (median follow-up of 29.6 months [range, 22.3 to 61.4]) 30:13. 85:26. Median pretreatment ALT level in U/liter (range). 56 (9

The Clinical Value of Oxymatrine in Preventing Lamivudine Induced

The tyrosine-methionine-aspartate-aspartate (YMDD) is one of the most common HBV drug-resistance mutations, which is in the catalytic domain C